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Chapter 1: Significance of the Problem 
 
Human Immunodefficiency Virus (HIV) protease (HIVP) is an enzyme critical for the 
maturation of the virus. The protease plays a critical role in viral assembly. The 
protease cleaves the viral polyproteins gag or gag-pol at nine non-homologous sites 
(Table 1) to yield separate structural proteins and enzymes, including the protease 
itself, essential for the viral life cycle (Figure 1) (11).  Hence, the most potent 
medications currently available for treatment of Acquired Immunodeficiency 
Syndrome (AIDS), caused by HIV, are the inhibitors of the viral protease (3).  These 
agents in combination with other agents comprise highly active antiretroviral therapy 
(HAART).  
  
The active site of this aspartyl protease is located at the interface of the dimers and 
each monomer contributes an aspartate residue, which is part of an Asp-Thr-Gly triad.  
The interactions of HIVP with its natural substrates represent an interesting example 
of recognition of asymmetric substrates by a symmetric enzyme. The natural peptide 
substrates bind to HIV-1 protease in an extended conformation with eight contiguous 
residues on the peptide, labeled P4 to P4', making contact with the eight enzyme 
subsites S4 to S4' (Figure 2) (12). Insight about the interactions of the substrates with 
HIVP has been gained from crystallographic studies of substrates bound to a form of 
the enzyme that has been inactivated by mutating the catalytic aspartic acids to 
asparagines (11). From their analysis of six crystal structures with an inactive (D25N) 




HIV-1 protease is based largely on shape, which is conserved across substrates, rather 
than on the detailed amino acid sequences of the substrates (13). This view is 
corroborated by the fact that the nine substrate sequences cleaved by the protease 
differ significantly in their amino acid sequence, but fill very similar volumes within 
the active site, when bound. The shape defined by the van der Waals volume of the 
substrates in the active site of the protease has been termed the “substrate envelope” 
(Figure 3a & 3b).  
 
The currently available, FDA approved, HIV-1 protease 
inhibitors act by binding to the active site of the protease. However, they can become 
ineffective due to mutations in the protease that diminish the affinity of the inhibitors 
but do not prevent the cleavage of the natural substrates of the enzyme. The drug-
resistant mutations appear due to the high replicative rate of HIV, the infidelity of the 
reverse transcriptase and the selective pressure of protease inhibitor therapy on the 
evolution of the virus.  Hence, there is a continuing need for novel multi-targeted 
inhibitors of HIVP. The present project forms part of a larger, collaborative effort to 
develop protease inhibitors that effectively inhibit not only wild type but also mutant 
forms of HIV protease. 
 
Structure-based virtual screening of chemical libraries or 
optimization of lead compounds obtained from such screenings, have become 
valuable tools in drug development and the development of the existing HIVP 




based design essentially requires an understanding of the physical interactions 
between small molecule inhibitors and their target. Better elucidation of the factors 
influencing binding of HIVP and its inhibitors will facilitate the discovery of novel 
drug molecules, especially when combined with the extensive set of crystal structures 
of HIVP, both wild type and mutants, complexed with inhibitors and substrates that 
have become available (7). The binding affinities of many inhibitors to both wild type 
and mutant HIVPs have also been published. These data include the affinities of the 
cyclic urea inhibitors of HIVP (12-14). The binding affinities of this class of 
compounds span a wide range, providing the scope to optimize and test models of 
binding with a varied set of ligands. In addition, the experimental data for the cyclic 
ureas are likely to be consistent because they are from a single laboratory. The data 
for this set of ligands have been used extensively in the present study. 
 
Structure-based design of HIVP inhibitors targeted against both 
wild type protease but also mutants will involve adequate ranking of the binding 
affinities of potential ligands. Binding affinity predictions of HIVP inhibitors using an 
empirical force field like CHARMM (8) combined with a continuum solvation model 
(9) have yielded promising results in a previous study (10). Although the method was 
not highly accurate, it did appear to have significant predictive value. However, the 
prior method is limited by its use of computationally expensive detailed calculations 
of configurational integrals for energy minima. In this project an energy model is 
being parameterized with the goal of developing a fast  method for predicting binding 




screening to discover new potential anti-HIV drug candidates. After such a lead drug 
molecule is obtained from virtual screening, its chemical structure usually must be 
optimized by chemical modifications to enhance its binding affinity to the receptor. 
 
In recent years, lead optimization procedures have been published which work by 
minimizing the electrostatic part of the binding free energy by adjusting the ligand’s 
atomic charges to maximize the complementarity of its charge distribution with that 
of the binding site. However, the existing computational procedures optimize the 
charge distribution of the whole ligand, so the charge changes suggested for a given 
part of the ligand may be based upon the assumption that charges elsewhere in the 
ligand also are changed. This assumption will frequently be a poor one, since 
chemical modifications of a lead compound are usually local in nature. Thus, local, 
rather than global, charge optimization should provide more accurate guidance for 
ligand modification. A central element of the present project is a method of 
optimizing the charges of local parts of a ligand while keeping the rest of the charges 
roughly constant, rather than attempting to modify all of the ligand’s charges towards 
a computed optimum, as done in previous approaches.  
 
The method developed here will also be computationally faster than existing 
approaches because it will require only one Poisson-Boltzmann calculation for the 
free ligand and one more for the bound ligand, while existing methods require two 
Poisson-Boltzmann calculations for each charge center of the ligand. The design 




Chapter 2: Background 
 
2.1 Parameterization of an Energy Model 
 
An energy model, described below, is being tuned by fitting to 
experimental binding affinities of a training set of ligands by downhill simplex 
minimization (11), with the aim of using the parameterized model for scoring ligands 
according to their binding affinities to their target receptors. The parameterized 




The binding energy of a ligand is the free energy change on 
complex formation of the ligand with its target protein: 
                     K 
                                  L  +  P      PL.          (1) 
 
The binding energy of a ligand can be calculated as the difference between free 
energy of the complex, the free ligand and the free protein: 
 





where K is binding affinity of the ligand, L, and GX is the free energy of the 
subscripted species. 
 
Influences that stabilize the complex are dispersion forces, charge-charge 
complementarity, hydrogen bonding, and hydrophobicity. In the present energy 
model, the first three driving forces are explicitly accounted for by Lennard-Jones and 
electrostatic terms that form part of the empirical force field CHARMM22.  Thus, the 
van der Waals interaction between atoms i and j is approximated as 12-6 Lennard-
Jones potential 
 
ULJ = 4ij { (/rij)12 - (/rij)6 },      (3) 
 
where, rij is the distance between atoms i and j,  is the mean radius of atoms i and j, 
and ij is a constant for the atom pair. The electrostatic Coulombic energy is 
computed according to Coulomb’s law as 
 
UCoulombic = qiqj / Drij ,              (4) 
 
where D is the dielectric constant of the medium and qi is the charge on atom i. The 
force field also includes a term that accounts for intrinsic energy changes associated 
with bond rotations. This dihedral energy term is proportional to the cosine of the 
dihedral angle under consideration.  The hydrophobic effect is accounted for 





WNP = C A    (5) 
 
where A is the surface area, which falls when two molecules bind to form a complex, 
and C is a coefficient fitted to reproduce measured solvation energies of nonpolar 
compounds in water.  It is also possible to allow the surface area component to 
account for the van der Waals dispersion forces between ligand and protein, and 
variant models were tested in which the Lennard Jones term was omitted, as 
described below.  
 
Influences that destabilize the complex are desolvation of polar groups and loss of 
translational, rotational, configurational entropies. The Poisson Boltzmann solvation 
energy accounts for desolvation penalty paid for complexation. Here, the electrostatic 




where [ ( ) ( )]D r rφ∇• ∇  is the divergence of the displacement field, ( )rρ  is the 
charge density as a function of the position r, 
2( ) ( ) ( )oD r r rε κ φ gives a measure of the 
screening effect of the salt in solution, D(r) is the position dependent dielectric 
constant having a particular value in the molecular region (Dint) and a second value 
in the solution region and the ion-exclusion region (Dsolv). Here 
2 ( )rκ  is given by 












   (7) 
where I(r) is the ionic strength as a function of position, k is the Boltzmann constant 
and T is the temperature in Kelvin. Note that the ionic strength is zero inside the 
solute and so 
2 ( )rκ is also zero there.  The Poisson-Boltzmann can be solved using 
numerical techniques, such as the finite difference method. This method discretizes 
the continuum electrostatics problem onto a 3D grid, where the dielectric constants 
are coded onto the grid lines and the charges and ionic strength are coded onto the 
vertices of the finite difference grid, thereby transforming the Poisson-Boltzmann 
equation into a set of difference equations, which can then be solved by standard 
techniques of linear algebra. 
Then the electrostatic energy can be calculated as: 
 











.  (8) 
 
The number of rotatable bonds (Ntor) of a ligand is considered an approximate 
measure of configurational entropy loss. Rotational and translational entropies are 
difficult to compute. Here, it is assumed that these changes are about the same for all 
inhibitors. As a consequence, this term cancels when one considers relative binding 






In summary, for a molecular species i, the potential energy is 
calculated as the sum of the Lennard-Jones, Coulombic and dihedral energy terms 
 
Ui  = ULJ,i + UCoulombic,i + UDihedral,i   (9) 
 
and the solvation energy for the species i is computed as the 
sum of the polar, Poisson-Boltzmann component (PB) and the non-polar surface area  
(NP) terms: 
 
 Wi  = WPB,i + WNP,i .   (10) 
 
The total free energy for the species i, is then, calculated as the 
sum of potential and solvation energies:  
 
Gi  = Ui  + Wi.        (11) 
 
                                     Treatment of multiple conformations 
 
A detailed physical model of the binding process of a ligand to 
its receptor considers an ensemble of conformations of the free ligand, and of the 
ligand in the complex, where the free energy of each conformation can be calculated 
according to equation (11). The free energy of the species can then be computed as 




in equation (12). To account for the configurational entropy change, a term 
proportional to the number of rotatable bonds of the ligand is added to that energy. 
The resulting expression for n conformations of the free ligand is: 
 
GL = -RT ln Σn e - Gi /kT  +  c Ntor.  (12) 
 
Similarly, for an ensemble of n conformations of the 
complexed ligand, the free energy of the ligand in complex (GPL) is calculated as the 
Boltzmann sum of the free energies of all the conformations: 
 
GPL = -RT ln Σn e - Gi /kT   (13)  
 
Here it is assumed that the ligand’s bonds are no longer 
rotatable, so the additional term of Equation  (12) is omitted.  
 
In the present method, multiple conformations of the free 
ligand are generated in the absence of the protein, and their energies are computed 
and combined as described above.  Similarly, multiple conformations of the ligand-
protein complex are generated, with the protein part currently held rigid, and again 
the energies of the conformations are computed and combined.  When all the ligands 
in a series are modeled as binding to exactly the same protein sequence and structure, 
then the internal energy of the protein conformation is a constant in the calculations 




However, when different ligands are fitted into different conformations of the 
protease, and/or different mutants, then the computed binding energy includes not 
only ligand-protein interactions but also differences in the internal energy of the 
protein.  Some of these changes result from conformational differences that are 
unrelated to binding and result from arbitrary details such as the arrangement of side-
chains far from the binding site, depending upon the crystal structures used. If any 
useful signal is to be obtained from the calculations, it is important that these rather 
random energy components be eliminated.  This can be done by forming a model of 
the free protein, for each conformation used, which consists of the complexed 
conformation of the protein without the ligand, and then subtracting the free energy of 
this isolated protein from that of the complex. 
 
 
                                    2.2 Optimization of Lead Drug Compound 
 
Computational ligand design and optimization in drug 
discovery 
 
Computer-aided drug design involves the design of compounds 
that bind with high affinity to key regions of biologically important molecules like 
enzyme active sites, leading to inhibition or alteration of the activity of the target.  A 
rational strategy for ligand design may involve de novo design of a potential lead 




binding affinity for the targeted receptor. Several methods of de novo ligand design 
and/or optimization of lead compounds exist, of which some representatives are now 
discussed.  
 
One way to optimize an existing ligand is to manually modify 
it via computer graphics software and study the new interactions of the modified 
ligand with the receptor using three-dimensional molecular graphics programs like 
QUANTA and Insight (1).  However, it is difficult to test many possible changes by 
this approach, and hence several automated approaches have been developed. 
 
A more detailed and automated approach (2, 3) involves the 
use of the multiple copy simultaneous search (MCSS) method, which is suitable for 
both de novo construction of ligands and optimization of known ligands. In the de 
novo design mode, the MCSS method uses molecular dynamics with the CHARMm 
force field (4) to search for optimal positions and orientations of small chemical 
fragments, each with a single functional group in most cases, in the binding site of the 
targeted receptor. Fragments in these favored positions are subsequently connected to 
form candidate ligands. An appropriate set of chemical fragments is one in which 
most organic molecules can be described as a collection of such groups. Functional 
groups that may be considered are acetonitrile, methanol, acetate, methyl ammonium, 
dimethyl ether, methane, acetaldehyde and isobutane.  Such groups are simple enough 




enough to approximate the steric and electrostatic interactions of a chemical moiety 
forming part of a complete ligand.  
 
To optimize a known ligand with the MCSS method, set of 
functional groups is chosen so that the desired ligand may be reconstructed. The 
functionality maps obtained from the MCSS method may then indicate ways of 
modifying an existing ligand to improve its binding affinity for the receptor. For 
example it may be observed that a different stereochemistry is required for formation 
of additional hydrogen bonds by the ligand with the receptor. Another approach may 
be to determine whether a fragment finds a low-energy position next to an existing 
ligand. Such fragments may be chemically linked to the ligand to increase affinity. 
  
A third approach to ligand optimization involves automatically 
linking new groups to an existing ligand or scaffold. Implementations of such an 
approach are found in the programs LUDI (5) and GROW (6). LUDI makes use of 
statistical data from small-molecule crystal structures to determine possible binding 
geometries of a ligand that interacts with hydrogen bonding and hydrophobic sites of 
the receptor. The small molecules are then iteratively linked, and the growth process 
is evaluated with a simple energy function that has terms to account for hydrogen 
bonding, ionic interactions, lipophilic interactions, and changes in ligand entropy due 
to freezing of internal degrees of freedom. GROW, used for ligand design by Moon 
and Howe, utilizes a template set and iteratively pieces the library templates together, 




GROW can be used for ligand optimization by determining whether the existing 
ligand should have a different stereochemistry or by adding functional groups to the 
existing ligand to enhance the computed binding affinity. 
 
The above approaches all use simplistic treatments of 
electrostatic interactions, which are widely believed to be important determinants of 
affinity. For example, they all neglect the energy cost of desolvating polar groups 
upon binding.  Also, all the methods described above rely upon trial and error during 
ligand construction, rather than taking a guided approach to speed the construction of 
improved ligands. This tends to make the calculations costly. The main theme of the 
present project is to utilize a full electrostatic model, including both Coulombic 
interactions and desolvation penalties for polar groups, to design and/or optimize 
ligands. Gradients of the binding free energy with respect to atomic charges are used 
to guide ligand modifications and thus speed the process. The following sections 
describe the electrostatic model used here, and the gradient-based optimization 
procedure.  
 
                                Detailed Description of Continuum model of molecular 
electrostatics  
                               In the binding reaction of a ligand with a receptor in an aqueous 
solution, interactions with the solvent and intramolecular Coulombic interactions in 
the unbound states are exchanged for intermolecular interactions between the ligand 




the binding free energy is thus the result of a delicate balance between the ligand-
receptor Coulombic interaction and desolvation effects. This balance is captured by a 
continuum electrostatics model (7) (Figure 4), which describes the ligand and 
receptor as low-dielectric regions with embedded charges surrounded by high 
dielectric solvent. 
 
The total electrostatic energy of a molecule or a complex of 





elec i iG qφ= ∑   (14) 
where iq  is the charge on atom i and iφ  is the electrostatic 
potential at atom i. 
  The electrostatic potentials at an atom can be obtained by 
solving the linearized Poisson-Boltzmann equation as described earlier. 
Given the electrostatic potentials from a solution of the 
linearized PB equation, the total electrostatic free energy of assembling solute charges 
from infinite separation into a cavity with dielectric constant, Dint, surrounded by an 
external continuum medium with dielectric constant, Dsolv, is given by, 
1 1




elec i i i i iG q qφ φ φ= = +∑ ∑   (15) 
where N is the total number of solute charge centers, φi is the 
potential at the position of charge qi, and φiC and φiR are the Coulomb and reaction 
field potentials, respectively. The reaction field potential is due to the polarization 


















= =       (16) 
 
where ( )ci jrφ  is the potential produced by charge located at 
position ir , at the position jr , ijb is a proportionality constant, intD is the dielectric 
constant inside a molecular cavity, 0ε  is the permitivity of vacuum and ijr  is the 
distance between charges at positions i and j. 
The reaction field potential at position of charge qi induced by 
a charge qj is proportional to the charge qj and opposite in sign  
 
R
i ij jc qφ =   (17) 
 
where ijc  is a proportionality constant less than zero whose 
value depends on the shape of the molecule or complex and position of the charges. 
Consequently, for both the free ligand and the complex the electrostatic free energy 
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where the first term in the right-hand-side is the interaction of 
charge i with the reaction field potential induced by charge i itself, and the second 





When a ligand binds a receptor the change in Coulombic 
interaction is usually favorable due to the complementarity of the charge distribution 
of the ligand and the receptor binding site, while the desolvation of the ligand can be 
expected to be energetically unfavorable due to stripping of solvent molecules from 
the polar parts of the ligand and receptor. Consequently, in most complexation 
reactions, monotonically increasing the charge of the ligand makes the Coulombic 
interactions more favorable but makes the desolvation penalty more unfavorable.  
Hence, in order to maximize binding affinity the charge distribution on the ligand 
should be adjusted so that the gain in Coulombic interactions upon binding is 
maximized, while the desolvation penalty is minimized. 
 
Recently, the Tidor and Purisima groups have developed the 
concept of electrostatic optimization of ligands (8-9) showing that there exists a 
single charge distribution that optimizes the binding energy of the ligand for a 




This result can be understood as follows. In equation 18 the coefficient of the 
quadratic terms for the free ligand or the complex is given by 
1i
R
i i qc φ ==  (19) 
where 1i
R
qφ =  is the reaction field potential at charge i induced by 
a unit charge located at the position of qi. This quantity is always negative based upon 
equation 17. As a result the electrostatic free energy of the free ligand and the 
complex are parabolic functions of charge with the parabolas opening downward. The 
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(20) 
Here the coefficients with superscript “c” are for the complex, 
the coefficients with the superscript “f” are for the free ligand and receptor, aii denotes 
the difference of the cii coefficients, and aij denotes the sum of differences of the bij 
and cij coefficients.  Normally, the ligand interacts more strongly with the solvent 
before it is bound rather than after, so the reaction field felt by qi is usually smaller in 
magnitude in the complex than in the free ligand. This implies that c fii iic c>  and hence 
aii is always positive. As a consequence, the electrostatic free energy of binding 
elecGΔ  may be represented by an N-dimensional parabola that is concave up and has a 




to this minimum are expected to optimize the binding affinity of the ligand and 
receptor.  
 
Traian and Purisima showed that the concept of optimal 
charges holds good for systems with irregular dielectric boundaries, such as a host-
guest complex of 18-crown-6 ether with alkali metal ions, a complex of calcium with 
the calcium-binding protein carp parvalbumin, and the complex of the covalent 
epoxysuccinyl inhibitor CA030 with human cathepsin B (9). Kangas and Tidor 
showed that an endo-oxabicyclic transition-state analogue of the enzymatic reaction 
of chorismate mutase from Bacillus subtilis, which exhibited good electrostatic 
affinity for the protein, had charge distribution complementary to the enzyme active 
site throughout much of the binding site, but had potential for improvement at a 
carboxylate since that group paid a substantial desolvation penalty upon binding and 
did not recover significant compensatory electrostatic interactions with the enzyme 
(8). Their calculations showed that replacement of the carboxylate group with the 
isosteric nitro group should improve electrostatic binding energy by 2-3 kcal/mol due 
to a decrease in the desolvation penalty of the ligand and smaller losses in other 
electrostatic interactions.  The above prediction was qualitatively, though not 
quantitatively, borne out by experiment (10). 
 
The published charge optimization methods described above 
have yielded promising results but are based on the optimization of charges over the 




requirements for favorable charge complementarity between the ligand and the 
receptor and consequently may provide inaccurate guidance for lead optimization. 
For instance, in the complex of HIV-1 protease with its inhibitor saquinavir, the 
negative charge on the catalytic aspartates of the protease means that nearby ligand 
atoms prefer to become more positively charged in order to maximize affinity.  The 
optimal positive charges at these locations effectively screen the negative potential 
produced by the aspartyl groups, so that more distant atoms may now prefer to be 
more negative, depending upon their local environment. However, if the charges of 
ligand atoms near the aspartates are held fixed while optimizing more distant atoms, 
then the more distant atoms can still feel the negative potential of the aspartates and 
may prefer to become more positively charged as a consequence.  Thus, local 
optimization of charges may produce quite different results from global optimization.  
The methods of Tidor and Purisima require a separate PB 
calculation for each ligand charge and hence is computationally slow. The present 




Chapter 3: Methods 
3.1 Parameterization of an Energy Model 
 
For the free ligands, twenty low-energy conformations were 
identified by using a conformational search method implemented in our laboratory’s 
in-house software (15). For the sake of computational speed and simplicity, bond 
lengths and bond angles are held fixed. Thus, for the free ligand, only torsional angles 
were allowed to vary, while for the complexes, the position and orientation of the 
ligand also was included in the search.  During the search, energies were computed 
with the empirical force field CHARMM, with a distance-dependent dielectric 
constant to account approximately for the tendency of the high-dielectric solvent to 
weaken electrostatic interactions.  The low-energy conformations that resulted were 
then post-processed to yield energies according to the model described above, with 
fitted coefficients as described below. 
For bound ligands, the method of generating conformations depended upon whether a 
crystal structure of the complex was available. For all but one of the cyclic ureas 
considered, no crystal structure is available. The missing bound conformations were 
therefore generated by docking these compounds into the crystal structure 1hvr, 
which was solved with a cyclic urea inhibitor bound. The dihedral sampling range 
was  +/-180°, the translational search range was a cubic translational box with side of 
10A, and the rotational sampling ranges were +/-180°.  For ligands for which crystal 
structures are available, the ligands were locally optimized around the known 




dihedral except for hydroxyl hydrogens, which are sampled in the range of +/-180°, a 
cubic translation box with side 1A, and rotational sampling ranges of  +/-5°.  Such 
minimizations allow little deviations from the crystal structure conformations of the 
ligands but avoid interatomic clashes while using the force field of our choice, since a 
different force field might have been used to refine the crystal structures. During 
these samplings, protein is considered rigid.  
 
For conformation, electrostatic energies and surface area energies are computed using 
UHBD (17). The free energy of free ligand and the ligand in the complex is computed 
as the Boltzmann sum of the energies of 20 conformations of the respective species, 
as described above, and the unbound protein’s energy is approximated as described 
earlier. Relative binding energies of the ligands are calculated for each ligand with 
reference to a specific ligand, chosen arbitrarily, as the difference between the 
binding energy of the former and the reference ligand:  
 
 GL = GL - GReference Ligand.  (21)  
 
 
 The relative theoretical binding energies are fitted against the relative experimental 
binding energies for parameterization of the energy model. The experimental binding 
energies are calculated from dissociation constants of ligands as shown above in 




respect to the ligand used as reference for calculation of relative calculated binding 
energy:  
 
GL = GL - GReference Ligand   (22) 
 
 
The root mean square deviation (RMSD) of relative calculated 
and relative experimental binding energies serve as the measure of error in the 





An initial plot of experimental and calculated binding energies 
of the cyclic ureas with HIVP (Fig 6a & b) showed a poor correlation between the 
experimental and theoretical values and we conjectured that, although the energy 
terms might be basically reasonable, the final results are poor because the terms are 
not well balanced.  Therefore, fitted scaling terms are used for computation of 
binding energies, as has been done by other authors in parameterizing energy models 
with different functional forms (20). The raw energy terms are, hence, scaled prior to 
computing binding affinities. For each conformation of L or PL,  and the suitable 






Gscaled,i =  α ULJ,i + β UCoulombic,i + γ Udihedral,i + δSntor + ε WPB,i  + 
ςWsurface area energy,i +    
                   (24) 
 
The additional coefficient, , takes into account any error in 
the calculated binding affinity of the reference ligand. RMSD of scaled theoretical 
affinities relative to experimental are minimized using “Down Hill Simplex” 
algorithm (11). This minimizer was chosen because it is a robust local optimizer 
capable of minimizing single-valued functions in multiple dimensions. It is not 
constrained by conditions like monotonocity, convexity or differentiability of the 
function optimized. It performed reasonably fast for our purpose. 
 
The experimental data, consisting of ligands and their 
affinities, were separated into training and test sets.  Initially, a set of 60 cyclic ureas 
(Fig 7) with dissociation constants (Kds) ranging from 0.25 nM to 21000 nM (12-14) 
was used as the training set for parameterization of the energy model, and another set 
of 20 cyclic ureas with Kds ranging from 0.41 nM to 25000 nM was used in the set to 
test the optimized model.  In addition a set of ligands, with chemical structures 
different from the cyclic ureas and having dissociation constants ranging from 0.02 
nM to 2300 nM was added to the test set. Crystal structures of this latter set of ligands 
are known. The latter set of ligands contained the FDA approved drugs presently 





Several variants of the energy model were parameterized and 
tested for correlation of experimental and predicted binding energies. Models both 
including and excluding van der Waals energies, solvation energy models with 
protein dielectric constants of 1 and 20 and energy models with and without Poisson-
Boltzmann solvation terms were tested. Moreover, different protonation states of the 
critical catalytic aspartate residues of HIVP were evaluated for agreement between 
theoretical and experimental energies. For each case the lowest test rmsd case was 
chosen from amongst 25 optimization runs.  The RMSD and Pearson’s correlation 
coefficient between the experimental and calculated binding energies were used to 
evaluate efficiencies of the energy models. 
3.2 Optimization of Lead Drug Compounds Theory 
In preliminary studies, I have shown that one can improve the 
charge distribution of ligands to optimize binding, within the context of continuum 
electrostatics, by a much faster, simpler and more accurate method than those 
previously described in the literature.  From Equation 20 the derivative of 
electrostatic binding energy with respect to charge is,  
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Thus, the derivative of the change in electrostatic binding 




binding.  This quantity can be computed from two linearized Poisson-Boltzmann 
solutions, one for the free ligand and one for the bound ligand, and it can be used to 
predict the change in electrostatic binding energy for a given change in qi. Thus, it is 
conjectured that these derivatives can be used to guide the chemical optimization of 
an existing ligand. For example, it should be advantageous to replace an atom for 
which the change in potential upon binding is very positive with a more 
electronegative element, and vice versa.  More particularly, one can use the 
derivatives from Equation 25 to predict the change in the electrostatic part of the 
binding energy, when a set of charges i is changed, as 
 
 ( )c felec i i i
i
G qφ φΔΔ ≈ − Δ∑  (26) 
It is expected that the best results will be obtained for atoms 
with large gradients because, as can be seen from the parabolic plot of the 
electrostatic binding energy against charge (Figure 5), charge changes at atoms with 
low gradients risk overshooting the optimum and may even yield worse binding. 
 
I tested whether it was actually possible to use energy gradients 
to predict the change in electrostatic binding energy of a ligand when its charge is 
changed.  This was done by studying the electrostatic component of the binding free 
energy of HIV protease with inhibitors XK263 and saquinavir, as well as cytosine 
deaminase with one of its inhibitors, using for now the assumption that the ligand 
keeps the same conformation in solution as in the bound complex. The crystal 




PDB codes for the complexes with XK263, saquinavir and the cytosine deaminase 
inhibitor are 1HVR, 1HXB and 1CTT respectively. The aspartyl dyad of HIV 
protease was considered to be monoprotonated and the crystal water was retained in 
the calculations for the saquinavir. The conformations of the free ligands were taken 
to be the same as in the bound complexes. The partial atomic charges of the ligands 
were calculated using Vcharge (14), and the receptors were assigned CHARMm 
charges with the program QUANTA (4). The linearized Poisson-Boltzmann equation 
was solved with the program UHBD (15), using a solute dielectric constant of 1 
initially for the HIV protease systems and 4 for the cytosine deaminase inhibitor. The 
solvent dielectric constant used was 78.5, since the complexation reaction was 
assumed to take place in an aqueous medium. The solvent was considered to have 
physiological ionic strength, 150 mM. An ion-exclusion zone defined with a probe of 
radius 2 A was used. The dielectric constant in this region is that of the solvent, but 
the ionic strength is zero. The cubic grid used for the HIV protease calculations had a 
side length of 110 grid units and a grid spacing of 0.25 Angstroms; the corresponding 




Chapter 4: Results and Discussion 
 
4.1 Parameterization of Energy Model 
Optimization of the model for cyclic urea ligands of HIV protease 
 
Amongst the variants of energy models compared, the model 
excluding van der Waals term and using protein dielectric constant of 20 for 
electrostatic energy calculations, gave the highest correlation between calculated and 
experimental binding energies. The diprotonated HIVP yielded the best-predicted 
binding energies.  This model yielded a Pearson’s correlation coefficient (r) of 0.55 
between calculated and experimental relative binding energies, for the test cyclic 
ureas (Fig 7), when energy coefficients were optimized with a training set having 
cyclic urea ligands only. The coefficients from optimization of these energy terms are 
shown in Table 2.  When the Poisson-Boltzmann energy component was omitted 
from the model and the coefficients were re-optimized, the resulting correlation 
coefficient between calculated and experimental binding energies was somewhat 










Testing the model on a broader set of HIVP  ligands 
 
When the model trained on cyclic ureas was tested on a 
broader set of ligands, the correlation coefficient for the test set fell to 0.09 (Fig 9). 
Interestingly, however, a high correlation coefficient of 0.62 was found for the subset 
of new ligands whose scaffold was most similar to that of the cyclic ureas  (Fig 10).  
On addition of a subset of the broader set of ligands to the training set and re-training 
the model, the results improved. The overall correlation coefficient was still 0.03, but 
removing the only outlier increased the r-value to 0.5 (Fig 11).  
 
Testing the model on a system other than HIVP 
 
We conjectured that part of the reason the correlations fall 
when the data set is expanded beyond the cyclic ureas is that the broader set of 
ligands was studied in different laboratories with different assays and under 
somewhat different experimental conditions. In contrast, all of the cyclic urea data 
were obtained at the same company under at least nominally uniform conditions.  In 
order to determine whether the model optimized with cyclic ureas alone would be 
transferable to a very different data set that had been obtained under its own uniform 
set of conditions, we applied the cyclic urea-derived model to a test set of Factor Xa 
inhibitors (18-19), without any further parameterization.  This yielded a correlation 
coefficient of 0.43, which is significantly better than that obtained for the broad group 








Optimization of the model for cyclic ureas ligands of HIV 
protease 
 
Due to approximation of van der Waals energy as 12-6 
Lennard Jones potential, small changes in interatomic distances can yield large 
changes in van der Waals energy. Consequently, even for a well-docked ligand, this 
energy term can have a large positive value due to proximity of a ligand and receptor 
atom. On optimization, the large van der Waals energies tend to force the Lennard-
Jones term to be assigned small, negative coefficients, which are physically 
meaningless (data not shown). Therefore, van der Waals energies were removed from 
the model and the surface area energies were allowed to take into account dispersion 
forces, hydrophobic effects and steric complementarity. The other energy term with a 
small negative coefficient was dihedral energy. However, the dihedral energy term is 
small and, hence, makes little contribution to the energy model. Therefore, the 
physically meaningless coefficients of dihedral energies are not a cause of concern.  
An interior protein dielectric constant of 20 reduced noise in Poisson-Boltzmann 
solvation energy calculations and, hence, gave better, predicted binding energies than 
a protein dielectric constant of 1. Though computation of Poisson-Boltzmann 




by the improvement in the predictive power of the energy model. Comparing the 
chemical structures of the various cyclic urea ligands with that of the outlier in Fig 7, 
shows that there exist compounds with very similar chemical structures (Fig 13), but 
while the outlier has a Kd of 25000 nM, the structurally similar compounds have Kds 
ranging from 1.4 to 51, suggesting that the experimental data for the outlier may be 
flawed.  
 
Testing the model on a broader set of HIVP ligands 
 
The same basic physical forces govern binding of any ligand to 
its receptor. Hence, theoretically, an energy model optimized for the HIVP-cyclic-
urea system should be valid for any receptor-ligand system. Such a general energy 
model should be expected to be good for predicting binding energies of any inhibitor 
of HIVP. The poor prediction we initially obtained for the binding energies of non-
cyclic-urea molecules necessitated probing factors that might be leading to loss of 
general applicability of the above energy model. One possibility we considered was 
that binding of structurally different ligands might change receptor conformations 
differently. Hence, upon complexation with ligands with widely different chemical 
structures, the receptor internal energy change is considerable.  There is wide 
variation in chemical structures of the non-cyclic-ureas. Consequently, conformations 
of the protein vary considerably between complexes of the non-cyclic-ureas. As a 
result, receptor internal energy change due to ligand binding needs to be taken into 




upon complexation is approximated in our calculations as the energy of the receptor 
conformation in the crystal structure of the receptor-ligand complex. This 
approximation may be inadequate, leading to the poor correlations between the 
experimental and calculated binding energies of the non-cyclic-ureas using a model 
optimized with cyclic urea training set. It was not required to consider protein internal 
energy changes for complexes with cyclic ureas because all the cyclic ureas were 
docked into the same crystal structure obtained from a complex of a cyclic urea with 
HIVP. Due to similar binding modes of the ligands, all the cyclic ureas were binding 
well in the aforesaid receptor. Also, relative binding energies with respect to a cyclic 
urea reference ligand were being considered in the calculations.  Consequently, 
changes in protein internal energy were largely cancelled in case of cyclic urea 
ligands. Due to similar reasons, the theoretical binding affinities of the cyclic-urea-
like ligands, amongst the non-cyclic-ureas, are in good agreement with their 
respective experimental values. Thus, the binding modes of the cyclic-urea-like 
ligands are similar to that of the cyclic ureas. Notably, a carbonyl O-atom of the 
cyclic ureas or cyclic-urea-like molecules interact with the flap Ile residues of HIVP. 
For other ligands a water molecule mediates the interaction of the ligand with the 
same Ile residues. Due to similar binding modes, change in receptor internal energy 
for the cyclic ureas and the cyclic-urea-like ligands can be expected to be close. 
 
In order to address this problem, an attempt was made to use 
ligand conformations obtained by docking of non-cyclic-ureas in the context of the 




ligands on the same footing with regard to the internal energy of the protein. 
However, a very low correlation coefficient of 0.03 was obtained between 
experimental and predicted binding energies of the non-cyclic-ureas. Here it needs to 
be mentioned again that same calculations for cyclic-urea-like ligands yielded a 
correlation coefficient of 0.62 between the predicted and experimental binding 
energies. However, it should be noted that the above problem was partially resolved 
when some of the non-cyclic-ureas were included in the training set, in addition to the 
original cyclic ureas (Fig 11).   
 
The catalytic aspartates of HIVP play an important role in 
ligand binding. In their complexes with HIVP, different ligands may induce different 
protonation states of these aspartates, but the protonation states of the critical 
aspartate residues are not known with any certainty. For cyclic ureas, the present 
calculations show that the diprotonated HIVP gives the highest correlation between 
experimental and predicted binding energies. However, the aspartate protonation 
states suitable for the ligands from crystals structures may be different from that of 
the cyclic ureas. The issues of these protonation states will be considered further in 
future work. 
 
Unlike the Kds of the cyclic ureas, the Kds of non-cyclic-ureas 
were obtained from different sources. The experimental conditions, like pH, 
temperature and ionic strength, used for determination of Kds of non-cyclic ureas 




calculated binding energies. For instance, lack of knowledge of the pH used for Kd 
determination make it hard to consider the correct ionization state of the ligands and 
proteins during binding energy calculations. 
 
 
                                  4.2 Optimization of Lead Drug Compounds 
 
I tested whether changes in ligand charges guided by 
electrostatic gradients (Equation 10) would in fact lead to a more favorable change in 
the electrostatic energy upon binding, as computed with full solutions of the PB 
equation. Thus, predicted changes in electrostatic binding energies (Equation 11) 
were compared with electrostatic binding energy (Equation 9) changes computed 
from the full solutions for the PB equation after the ligand modifications. In this 
process, I focused on the atoms at which the electrostatic gradients were high for 
reasons explained above.  I first looked at small artificial changes of single-atom 
charges, then at models of actual atom substitutions and small chemical additions that 
required recalculation of the partial charges of all the ligand atoms. Then I looked at 
serial modifications of a ligand, in which successive modifications were done 
according to the predictions based on the atomic electrostatic potential of the 
preceding version of the ligand.  For most of the above cases, the changes in ligand 
charges guided by electrostatic gradients improved the electrostatic binding energy 




in electrostatic binding energies from the predictions agreed reasonably well with the 
full electrostatic energy changes (Tables 3-7 & Figures 14-18).  
 
I began by making a series of artificial charge changes at one 
atom of XK263 with a gradient of  5.34 kcal/mol/e. The agreement is better when the 
magnitude of the change in charge is not very small or not very large (Table 3 & 
Figure 14). With very small changes in charge, discrepancies arise due to rounding 
errors in electrostatic energy calculations using numerical methods. With large 
changes in charge, the electrostatic gradient of the atom changes significantly due to 
addition of the charge, as expected based upon the parabolic form of Gelec, thereby 
giving rise to above-mentioned discrepancies.  
 
I then made a series of essentially isosteric hydrogen to 
halogen changes at high-gradient (4.4-8.2 kcal/mol/e) atoms in XK263. The changes 
in the electrostatic binding energies predicted from the gradients agree quite well with 
the changes obtained by a full electrostatic recalculation, (Table 4 and Figure 15), 
with a R2 value of 0.92. Most of the changes yield a more favorable electrostatic 
binding energy with respect to the original ligand, as expected according to the 
predictions. 
 
Next, functional group modifications involving additional 
atoms were made in the HIV protease inhibitor saquinavir, according to predicted 




original ligand atom. The changes in the electrostatic binding energies predicted from 
the gradients agree quite well with the changes obtained by a full electrostatic 
recalculation, (Table 5 and Figure 16), with a R2 value of 0.83. The electrostatic 
binding energies for the modified ligands did indeed become more favorable with 
respect to the original ligand, in accordance with predictions. For the modification of 
H14 of saquinavir to a hydroxyl group, the calculations were done for four different 
positions of the hydroxyl hydrogen. From such calculations it is observed that such 
rotatable bonds need to be in a particular orientation in order to improve the binding 
energy of the ligand.  
 
Functional group modifications involving additional atoms 
were made for the cytosine deaminase inhibitor, too.  Again, reasonable agreement 
was found between the changes in electrostatic binding affinities predicted based on 
the atomic electrostatic potentials and the computed changes in full electrostatic 
binding energies (Table 6 and Figure 17). The estimates and actual changes in 
electrostatic binding energies agree with a R2 value of 0.86. The electrostatic binding 
energies for the modified ligands were more favorable with respect to the original 
ligand, in accordance with predictions, as in the above cases. 
 
Sets of simultaneous multiple modifications in the cytosine 
deaminase inhibitor were not observed to improve the electrostatic binding energy 
markedly more than any of the isolated modifications (Table 6).  This may be 




and the optimum charge at another site, and thus yield unexpected results. In an 
attempt to resolve this problem, I made ligand modifications serially rather 
simultaneously. Serial modifications involve using the derivatives to guide an initial 
modification of the ligand, generating updated charges for the modified ligand, 
recomputing the atomic potentials of the modified ligand, and using these potentials 
to guide further modifications. The net outcome of the serial mutations turned out to 
be better than isolated modifications, as can be seen by comparing the improvement 
in electrostatic energy of the serial mutations (Table 7 and Figure 18) with the 
simultaneous multiple mutations done on the same inhibitor (Table 6). Also the 
estimates and actual changes in electrostatic binding energies agree with a R2 value of 
















Tables and Figures 
 
Table 
Peptide sequences Cleavage domains 
Cleavage sites in gag 
 
SQNY * PIVQ 
ARVL * AEAM 
ATIM * MQRG 
QANF * LGKI 









Cleavage sites in pol 
 
SFNF * PQIT 
TLNF * PISP 
AETF * YVDG 









Table 1: The nine non-homologous sites at which HIV protease cleaves the viral polyproteins 
gag or gag-pol to yield the structural proteins and enzymes essential for the viral life cycle. 
The cleavage sites are denoted by an asterisk. NC, nucleocapsid; MA, matrix; CA, capsid; 
TF, trans frame peptide; PR, protease; RT, reverse transcriptase; IN, integrase;RH, RNAse H. 








Energy Terms Coefficients 
Coulombic 1.08 
Dihedral -0.26 
Poisson-Boltzmann Solvation 2.03 
Surface area energy 0.57 
Number of Rotatable Bonds 0.05 
Offset(η) -2.53 
 



















Predicted change in 
electrostatic binding 
energy 
Full relative binding 
energy after artificial 
charge modification 
of ligand 












Table 3: Comparison of predicted changes in electrostatic binding 
energy based on the gradient at H66 of the original ligand and changes in electrostatic 
binding energies from full electrostatic calculations for the on artificial charge changes of 
H66 of the HIV protease inhibitor XK263.  The calculations were done with a protein 

















binding energy of 
modified ligand 
H66→Br 5.35 -0.277 -1.56 -1.16 
H66→Cl 5.35 -0.258 -1.37 -0.91 
H66→F 5.35 -0.339 -1.68 -0.74 
H47→Br 8.19 -0.303 -2.03 -2.03 
H47→F 8.19 -0.332 -1.44 -0.86 
H48→Br 3.88 -0.303 -0.74 -0.52 
H48→F 3.88 -0.332 -0.05 0.29 
H50→Br 6.99 -0.319 -3.78 -3.36 
H50→F 6.99 -0.335 -5.51 -4.66 
H57→Br 5.73 -0.277 -1.36 -0.68 
H57→F 5.73 -0.339 -1.16 -0.36 
H58→Br 4.39 -0.277 -1.08 0.16 
H58→F 4.39 -0.339 -0.90 0.38 
H67→Br 4.79 -0.277 -1.28 -0.59 
H67→F 4.79 -0.339 -1.22 -0.33 




H69→F 7.75 -0.339 -3.26 -2.60 
H71→Br 7.46 -0.292 -1.65 -0.84 
H71→F 7.46 -0.331 -1.06 -0.33 
H72→Br 6.16 -0.292 -1.28 -0.90 
H72→F 6.16 -0.331 -0.64 -0.37 
 
Table 4: Comparison of predicted changes in electrostatic binding 
energy based on the gradients of the atoms of the original ligand vs. actual changes in 
electrostatic binding energies from full electrostatic calculations for the modified ligand of 
the HIV protease inhibitor xk263 due to isosteric hydrogen to halogen changes. The 


























Full relative binding 
energy of modified 
ligand 
H14→OH 21.15 -10.14 -7.21 
H46→NH3+ -3.11 -1.01 -2.09 
H48→NH3+ -12.21 -1.18 -4.39 
-12.21   (atom 48) 
 
-10.72 H48→NH3+ + H49→NH3+ 
   -21.53  (atom 49)  
-18.53 
O34→NH3+ -15.61 -12.30 -11.51 
H50→OH -5.45 3.58 0.40 
H14→OH (rotamer1) 21.15 6.98 2.78 
H14→OH (rotamer2) 21.15 3.25 1.81 
H14→OH (rotamer3) 21.15 7.85 2.83 
H14→OH (rotamer4) 21.15 1.40 -2.12 
 
 
Table 5: Comparison of predicted changes in electrostatic binding 
energy based on the gradients of the atoms of the original ligand vs. actual changes in 
electrostatic binding energies from full electrostatic calculations for the modified ligand of 
the HIV protease inhibitor saquinavir due to functional group modifications involving 














Table 6: Comparison of predicted electrostatic binding energy based on the gradient of the 









A C2O3→SO2 -4.86 -3.03 
B C5H18H19→SO2 -0.08 -0.53 
C H19→F -1.53 -0.85 
D H27→OH -0.04 -0.47 
E O12→CH2 + H26→NH3+ -7.72 -4.60 
G H18→F + H19→F -0.31 -0.30 
F B + D -0.63 -1.26 
H D + G -0.89 -1.03 
I C + D -2.14 -1.54 
J A + B + E -2.39 -3.14 
K A + B + D + E -4.24 -3.61 




electrostatic calculations for the modified ligand of the cytosine deaminase inhibitor 3,4-
dihydrozebularine due to functional group modifications. The calculations were done with a 






















Table 7: Comparison of predicted electrostatic binding energy based 
on the gradient of the atoms of the original ligand and actual changes in electrostatic binding 
energies from full electrostatic calculations for the serial modifications of the cytosine 
deaminase inhibitor 3,4-dihydrozebularine. The calculations were done with a protein 

















C2O3→SO2 -4.86 -3.03 
C2O3→SO2 + H19→F -3.24 -5.06 
C2O3→SO2 + H19→COO- -3.45 -5.72 
C2O3→SO2 + H19→COCH3 -3.15 -5.75 


























Figure 1: The protease cleaves the viral polyproteins gag or gag-pol to yield structural 















Figure 2: Complex of HIV-1 protease with a natural substrate. HIV-1 
protease is represented by molecular surfaces and ribbon diagrams with subunit A in red and 
B in blue. A ball-and-stick representation of a natural polyprotein substrate (SQNYPIVQ) is 
bound in the active site. (a) View of the entire complex. (b) Close-up of the active site, with 















Figure 3: Substrate and inhibitor envelopes of HIV-1 protease. a) The substrate envelope 
from the overlapping van der Waals volume of four or more substrate peptides. The colors of 
the substrate peptides are: red, matrix-capsid; green, capsid-p2; blue, p2-nucleocapsid; cyan, 
p1-p6; magenta, reverse-transcriptase-ribonucleaseH; and yellow, rnaseH-integrase. b) The 
substrate envelope as it fits within the active site of HIV-1 protease. The alpha carbon trace is 
of the CA-p2 substrate peptide complex. c) The inhibitor envelope calculated from 
overlapping van der Waals volume of five or more of eight inhibitor complexes. The colors 
of the inhibitors are: yellow, Nelfinavir (NFV); gray, Saquinavir (SQV); cyan,  Indinavir 
(IDV); light blue, Ritonavir (RTV); green, Amprenavir (APV); magenta, Lopinavir (LPV); 
blue, Atazanavir (ATV) and red,  TMC114 d) The inhibitor envelope as it fits within the 
active site of HIV-1 protease e) Superposition of the substrate envelope (blue) with the 
inhibitor envelope (red). Residues that contact the inhibitors where the inhibitors protrude 
beyond the substrate envelope and confer drug resistance when they mutate are labeled. 




























Figure 4: In the binding reaction of a ligand with a receptor in an aqueous solution, 
interactions with the solvent and intramolecular Coulombic interactions in the unbound states 
are exchanged for intermolecular interactions between the ligand and receptor in the bound 
complex. L, R and RL represent the free ligand, the free receptor and the complex 
respectively. Dint, the dielectric constant in the cavities representing the free ligand, free 
receptor and the complex, is low in comparison with that of the aqueous medium, Dsolv. A 
charge embedded in the ligand is denoted by qi while a charge embedded in the receptor is 
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Figure 5: Variation of computed electrostatic free energy of binding, based upon full 
solutions of the linearized PB equation, with variation of charge on (a) buried atom (atom 49) 
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Fig 6. a. Fig 1 Cyclic urea scaffold showing the substituents corresponding to the S1, S2, S1’ 
and S2’ binding pockets of HIVP. b. Experimental vs. Calculated Relative Binding Energies 
without scaling. RMSD between experimental and calculated binding energies was as high as 






























































Fig 7: Plot of experimental binding energies Vs. calculated binding energies 
for training set (a) and test set (b) of cyclic urea ligands, when Coulombic, 
Dihedral, PB-solvation and Solvent accessible surface terms were included in 
the energy model. The result for lowest test set RMSD has been shown. 
Pearson’s correlation coefficients of 0.4 and 0.55 were obtained between 
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Fig 8: Plot of experimental binding energies vs. calculated binding energies for test set of 
cyclic urea ligands, when PB-solvation was excluded from the energy model. A correlation 
coefficient of 0.35 was obtained between calculated and experimental binding energies for 



































Fig 9: Plot of calculated vs. experimental binding energies of non-cyclic urea 
test ligands, when energy model includes Coulombic, dihedral, solvent 





























   
 
 
Fig 10: Plot of calculated vs. experimental binding energies of cyclic-urea-like test ligands, 
when energy model includes Coulombic, dihedral, solvent accessible surface area and PB-























Fig 11: Plot of experimental binding energies vs. calculated binding energies for training set 
(a) and test set (b) of cyclic urea ligands and ligands other than cyclic ureas, when energy 
model ss optimized with a set of ligands having both cyclic ureas and the non-cyclic-urea 
ligands. Correlation coefficients of 0.59 and 0.03 are obtained between calculated and 
experimental binding energies for the training and test sets respectively. Taking off the outlier 
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Fig 12: Plot of calculated vs. experimental binding energies of Factor Xa inhibitors (red) 
using energy model optimized with cyclic urea ligands and ligands other than cyclic ureas. 
Data are also shown for a test set of cyclic urea ligands (blue). The latter set is taken from the 
known crystal structures of HIVP-inhibitor complexes.  Pearson’s correlation coefficient for 
the Factor Xa inhibitors is 0.43. Errors in prediction of binding energies of Factor Xa 
inhibitors compare well with the error in estimates of binding energies of HIVP cyclic urea 
































a)     b) 
 
          
   Kd : 25000 nM    Kd: 51 nM 
 
Fig 13: A representative cyclic urea ligand with structure very similar to the outlier marked 
“A” in Fig 3. The  ligand in panel (a)  is the  outlier marked “A” while the one in panel (b) is 
the cyclic urea which structurally similar to the outlier.  The Kd values (nM) of the ligands  

















































Figure 14: Predicted changes in electrostatic binding energy based on the 
gradient of H66 of the original ligand versus changes in electrostatic binding 
energies from full electrostatic calculations for the artificial charge changes 




































Figure 15: Predicted changes in electrostatic binding energy based on the gradients of the 
atoms of the original ligand versus actual changes in electrostatic binding energies from full 
electrostatic calculations for the modified ligand of the HIV protease inhibitor xk263 due to 
isosteric hydrogen to halogen changes. The estimates and actual changes in electrostatic 




































Figure 16: Predicted changes in electrostatic binding energy based on the gradients of the 
atoms of the original ligand versus actual changes in electrostatic binding energies from full 
electrostatic calculations for the modified ligand of the HIV protease inhibitor saquinavir due 
to functional group modifications involving additional atoms. The estimates and actual 
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Figure 17: Predicted changes in electrostatic binding energy based on the gradient of the 
atoms of the original ligand versus actual changes in electrostatic binding energies from full 
electrostatic calculations for the modified ligand of the cytosine deaminase inhibitor 3,4-
dihydrozebularine due to functional group modifications involving additional atoms. The 
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Figure 18: Predicted changes in electrostatic binding energy based on the gradient of the 
atoms of the original ligand and actual changes in electrostatic binding energies from full 
electrostatic calculations for the serial modifications of the cytosine deaminase inhibitor 3,4-
dihydrozebularine. The estimates and actual changes in electrostatic binding energies agree 
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